Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
immuno-oncology
Pharma
AZ's Imfinzi keeps MIBC race against Keytruda hot with FDA nod
AstraZeneca has crossed the finish line in MIBC with its own doublet wedding Pfizer and Astellas’ Padcev with its PD-L1 inhibitor Imfinzi.
Fraiser Kansteiner
Nov 13, 2026 5:40pm
GSK's Jemperli snags FDA nod in rectal cancer after data buzz
Oct 19, 2026 1:24pm
FDA rejects Hengrui, Elevar PD-1 liver cancer combo a 3rd time
Jul 10, 2026 10:55am
BioNTech lays commercial groundwork for PD-L1xVEGF via HER2 ADC
Jul 9, 2026 2:17pm
Nature retracts provocative PD-1 time-of-day study
Jun 24, 2026 11:00am
Another AstraZeneca Emerald glimmers in liver cancer
Apr 2, 2026 10:12am